To explore the role of liquid biopsy comprehensive genomic profiling (CGP) in enhancing precision oncology, particularly in lung and breast cancer, and its significance in overcoming current testing limitations.
Key Findings:
Liquid biopsy can address limitations in tissue testing, especially in cases where tumor tissue is scarce, leading to improved patient outcomes.
ctDNA analysis captures tumor heterogeneity and resistance mechanisms better than single tissue biopsies, providing a more comprehensive view of the tumor.
The quickDNA initiative in Wales demonstrated reduced turnaround times for ctDNA testing compared to traditional tissue testing, facilitating quicker treatment initiation.
Interpretation:
Liquid biopsy serves as a complementary tool to tissue testing, enhancing access to genomic data, enabling quicker treatment decisions, and ultimately improving patient care.
Limitations:
Clonal hematopoiesis can confound ctDNA results, requiring advanced bioinformatics and matched normal sequencing to ensure accuracy.
ctDNA levels vary by tumor type and stage, affecting patient suitability for testing; understanding these dynamics is crucial for effective implementation.
Conclusion:
Liquid biopsy is a promising advancement in precision oncology, particularly for lung and breast cancer, facilitating earlier access to targeted therapies and improving patient outcomes through integration into standard clinical practice.
In just four years, the Fox Chase – Temple Urologic Institute has leveraged the expertise of two renowned institutions to deliver an exceptionally broad range of aligned and specialized urology and urologic oncology services, led by eminent clinicians and thought leaders.
